PE20191243A1 - Nuevos derivados de fenilo - Google Patents
Nuevos derivados de feniloInfo
- Publication number
- PE20191243A1 PE20191243A1 PE2019001339A PE2019001339A PE20191243A1 PE 20191243 A1 PE20191243 A1 PE 20191243A1 PE 2019001339 A PE2019001339 A PE 2019001339A PE 2019001339 A PE2019001339 A PE 2019001339A PE 20191243 A1 PE20191243 A1 PE 20191243A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- new derivatives
- methyl
- dinitrophenoxy
- intolerance
- Prior art date
Links
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- LRJQZGXEGNOHBH-UHFFFAOYSA-N 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole Chemical compound [N+](=O)([O-])C1=C(OCC2=CN=C(N2C)[N+](=O)[O-])C=CC(=C1)[N+](=O)[O-] LRJQZGXEGNOHBH-UHFFFAOYSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido a derivados de fenilo, 5-[(2,4-dinitrofenoxi)metil]-1-metil-2-nitro-1H-imidazol o una sal farmaceuticamente aceptable de este. Estos compuestos regulan la actividad de la mitocondria, reduce la adiposidad, trata enfermedades que incluye la diabetes, o resistencia o intolerancia a la insulina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443244P | 2017-01-06 | 2017-01-06 | |
| US201762581355P | 2017-11-03 | 2017-11-03 | |
| US201762585326P | 2017-11-13 | 2017-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191243A1 true PE20191243A1 (es) | 2019-09-16 |
Family
ID=61569353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001339A PE20191243A1 (es) | 2017-01-06 | 2018-01-05 | Nuevos derivados de fenilo |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10618875B2 (es) |
| EP (2) | EP3565806B1 (es) |
| JP (3) | JP7090088B2 (es) |
| KR (1) | KR102579648B1 (es) |
| CN (2) | CN110167918B (es) |
| AU (1) | AU2018205811B2 (es) |
| BR (1) | BR112019013371A2 (es) |
| CA (1) | CA3047138C (es) |
| CL (1) | CL2019001842A1 (es) |
| CO (1) | CO2019006865A2 (es) |
| DK (1) | DK3565806T3 (es) |
| ES (1) | ES2913431T3 (es) |
| GE (1) | GEP20217227B (es) |
| IL (1) | IL267868B (es) |
| LT (1) | LT3565806T (es) |
| MX (1) | MX2019007745A (es) |
| MY (1) | MY192778A (es) |
| PE (1) | PE20191243A1 (es) |
| PH (1) | PH12019501318A1 (es) |
| PL (1) | PL3565806T3 (es) |
| PT (1) | PT3565806T (es) |
| SA (1) | SA519402076B1 (es) |
| SI (1) | SI3565806T1 (es) |
| UA (1) | UA124026C2 (es) |
| WO (1) | WO2018129258A1 (es) |
| ZA (1) | ZA201903808B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| EP3565806B1 (en) * | 2017-01-06 | 2022-03-02 | Rivus Pharmaceuticals, Inc. | Novel phenyl derivatives |
| IL272941B2 (en) | 2017-08-28 | 2023-03-01 | Enanta Pharm Inc | Antiviral agents for viral hepatitis b |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| BR112021005091A2 (pt) | 2018-09-21 | 2021-06-08 | Enanta Pharmaceuticals, Inc. | heterociclos funcionalizados como agentes antivirais |
| CN113271946A (zh) | 2018-11-21 | 2021-08-17 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| IL308669A (en) | 2021-05-20 | 2024-01-01 | Rivus Pharmaceuticals Inc | Methods for the treatment of disorders related to mitochondria |
| MX2024009644A (es) | 2022-02-07 | 2024-08-14 | Rivus Pharmaceuticals Inc | Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada. |
| WO2023150767A1 (en) | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss and preserving skeletal muscle mass |
| WO2024112659A1 (en) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Crystalline forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1h-imidazole |
| WO2024112663A1 (en) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Deuterium enriched phenyl derivatives for treating mitochondriarelated disorders or conditions |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3828056A (en) * | 1972-09-11 | 1974-08-06 | Searle & Co | (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers |
| EG11928A (en) * | 1974-12-16 | 1979-03-31 | Hoechst Ag | Process for preparing of 1-alkyl-2-(phenoxy-methyl)-5-nitro-imidazoles |
| US5359078A (en) * | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
| ATE468114T1 (de) | 2002-11-08 | 2010-06-15 | High Point Pharmaceuticals Llc | Sichere chemische entkuppler zur behandlung von fettsucht |
| DE602004022153D1 (de) | 2003-05-14 | 2009-09-03 | High Point Pharmaceuticals Llc | Verbindungen zur behandlung von obesitas |
| MXPA05012679A (es) | 2003-05-27 | 2006-02-08 | Sod Conseils Rech Applic | Nuevos derivados de imidazoles, su preparacion y su uso como medicamento. |
| US20070010559A1 (en) | 2003-11-25 | 2007-01-11 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
| EP1689707A1 (en) | 2003-11-25 | 2006-08-16 | Novo Nordisk A/S | Novel compounds for the treatment of obesity |
| RU2006116421A (ru) | 2003-11-25 | 2008-01-10 | Ново Нордиск А/С (DK) | Анилиды салициловой кислоты |
| NZ565378A (en) | 2005-06-29 | 2011-03-31 | Threshold Pharmaceuticals Inc | Phosphoramidate alkylator prodrugs |
| WO2008059024A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
| CA2669884A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| EP2086951B1 (en) | 2006-11-15 | 2011-12-21 | High Point Pharmaceuticals, LLC | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
| EP2097380A1 (en) | 2006-11-15 | 2009-09-09 | High Point Pharmaceuticals, LLC | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
| ES2884674T3 (es) | 2008-10-21 | 2021-12-10 | Immunogenesis Inc | Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed |
| EP2179984A1 (en) | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| CN101560189B (zh) | 2009-05-20 | 2011-02-16 | 南京大学 | 甲硝唑和取代水杨酸的复合物及其制法与用途 |
| CN103168036A (zh) | 2010-06-24 | 2013-06-19 | 线粒体科技有限责任公司 | 温和的阳离子线粒体解偶联剂 |
| ES2784223T3 (es) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina |
| EP3038611B1 (en) | 2013-08-30 | 2024-04-17 | Yale University | Sustained-release pharmaceutical composition comprising 2,4-dinitrophenol |
| WO2015031598A2 (en) | 2013-08-30 | 2015-03-05 | Yale University | Therapeutic dnp derivatives and methods using same |
| CA2954004C (en) | 2014-07-03 | 2023-10-10 | NAN Global, LLC | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes |
| US20160008298A1 (en) * | 2014-07-14 | 2016-01-14 | Oregon State University | Xanthohumol-based compounds and compositions thereof, and methods of making and using the same |
| BR112017015721A2 (pt) | 2015-01-22 | 2018-04-10 | Mitochon Pharmaceuticals Inc | expressão induzida de fator neurotrófico derivado do cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas. |
| EP3426233A4 (en) | 2016-03-07 | 2019-10-16 | Mitochon Pharmaceuticals, Inc. | DNP-TREATMENT OF DNP PRODRUGS OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE DISEASES, DEVELOPMENTAL DISEASES, COMMODITY, DRY-LIKE SYNDROME, AND / OR METABOLIC DISEASES |
| EP3565806B1 (en) * | 2017-01-06 | 2022-03-02 | Rivus Pharmaceuticals, Inc. | Novel phenyl derivatives |
| EP3630115A1 (en) | 2017-05-22 | 2020-04-08 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using mitochondrial uncouplers |
-
2018
- 2018-01-05 EP EP18709129.3A patent/EP3565806B1/en active Active
- 2018-01-05 ES ES18709129T patent/ES2913431T3/es active Active
- 2018-01-05 PL PL18709129T patent/PL3565806T3/pl unknown
- 2018-01-05 MX MX2019007745A patent/MX2019007745A/es unknown
- 2018-01-05 LT LTEPPCT/US2018/012491T patent/LT3565806T/lt unknown
- 2018-01-05 PE PE2019001339A patent/PE20191243A1/es unknown
- 2018-01-05 GE GEAP201815132A patent/GEP20217227B/en unknown
- 2018-01-05 MY MYPI2019003195A patent/MY192778A/en unknown
- 2018-01-05 CN CN201880005988.7A patent/CN110167918B/zh active Active
- 2018-01-05 DK DK18709129.3T patent/DK3565806T3/da active
- 2018-01-05 UA UAA201906673A patent/UA124026C2/uk unknown
- 2018-01-05 US US16/475,390 patent/US10618875B2/en active Active
- 2018-01-05 CN CN202310980210.0A patent/CN117024351A/zh active Pending
- 2018-01-05 CA CA3047138A patent/CA3047138C/en active Active
- 2018-01-05 BR BR112019013371A patent/BR112019013371A2/pt active Search and Examination
- 2018-01-05 AU AU2018205811A patent/AU2018205811B2/en active Active
- 2018-01-05 JP JP2019537086A patent/JP7090088B2/ja active Active
- 2018-01-05 SI SI201830676T patent/SI3565806T1/sl unknown
- 2018-01-05 KR KR1020197018983A patent/KR102579648B1/ko active IP Right Grant
- 2018-01-05 PT PT187091293T patent/PT3565806T/pt unknown
- 2018-01-05 WO PCT/US2018/012491 patent/WO2018129258A1/en unknown
- 2018-01-05 EP EP22157494.0A patent/EP4086242A1/en active Pending
-
2019
- 2019-06-11 PH PH12019501318A patent/PH12019501318A1/en unknown
- 2019-06-12 ZA ZA2019/03808A patent/ZA201903808B/en unknown
- 2019-06-27 CO CONC2019/0006865A patent/CO2019006865A2/es unknown
- 2019-07-03 CL CL2019001842A patent/CL2019001842A1/es unknown
- 2019-07-04 IL IL267868A patent/IL267868B/en unknown
- 2019-07-07 SA SA519402076A patent/SA519402076B1/ar unknown
-
2020
- 2020-09-02 US US17/010,547 patent/US20200399225A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,168 patent/US20210238144A1/en not_active Abandoned
- 2021-10-28 US US17/513,235 patent/US20220048865A1/en not_active Abandoned
-
2022
- 2022-06-13 JP JP2022095049A patent/JP2022120118A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095420A patent/JP2024116328A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191243A1 (es) | Nuevos derivados de fenilo | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| BR112015029258A2 (pt) | compostos hetericíclicos como agentes de controle de pestes | |
| CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
| UA110653C2 (uk) | Фунгіцидна композиція і спосіб боротьби з хворобами рослин | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| EA201500953A1 (ru) | 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений | |
| BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
| CY1119118T1 (el) | Θεραπευτικος παραγων για τις διαταραχες της διαθεσης | |
| MX2015015168A (es) | Derivados heterociclicos y sus usos. | |
| CL2021000515A1 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| BR112016002383A2 (pt) | composto, composição herbicida, método para controlar plantas indesejáveis, e, uso de um composto | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| BR112018008006A2 (pt) | composto de piranodipiridina | |
| AR099767A1 (es) | Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2 | |
| DOP2018000134A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
| BR112015010823A2 (pt) | composto de 2-piridona | |
| MX2016011310A (es) | Agente para el control de endoparasitos. | |
| EA201991180A1 (ru) | Новые фенильные производные | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| MX2016011308A (es) | Agente para el control de endoparasitos. | |
| MD4317B1 (en) | Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating patients with advanced liver cirrhosis associated with heart failure |